• Wang-Da Liu, Sui-Yuan Chang, Ting-Yuan Lan, Yen-Chun Lin, Jui-Hung Kao, Chun-Hua Liao, Ming-Jui Tsai, Po-Hsien Kuo, Yu-Shan Huang, Jann-Tay Wang, Wang-Huei Sheng, Song-Chou Hsieh, Bor-Luen Chiang, Yee-Chun Chen, and Shan-Chwen Chang.
• Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. Electronic address: b95401043@ntu.edu.tw.
• J Formos Med Assoc. 2021 May 1; 120 (5): 126912731269-1273.

AbstractUntil now, there are no approved treatment against COVID-19. Hydroxychloroquine (HCQ) was hypothesized to be active against SARS-CoV2 via antiviral and anti-inflammatory effect; however, HCQ for COVID-19 in clinical use remained debating. In this preliminary report, we presented six patients with mild to moderate COVID-19. They were treated with HCQ for 14 days from the day of COVID-19 diagnosis. Serial viral load from respiratory specimens were performed every other day. Cytokine profile was checked before HCQ initiation and on the 14th day of HCQ treatment. All patients receiving HCQ completed 14-day course without complication. Among the six patients, the mean duration from symptom onset to last detectable viral load was 34 ± 12 days, which was similar to those without specific treatment in previous reports. Low level of interferon-gamma was noted in all patients of different stage of infection and three patients had elevation of IL-17 level. Prolonged virus shedding is still observed regardless HCQ. The impact of HCQ on cytokine kinetics remained unclear; however, IL-17 could be an inflammatory marker for disease status monitor and a potential therapeutic target.Copyright © 2020. Published by Elsevier B.V.

19 keywords...

hide…